期刊
BLOOD REVIEWS
卷 60, 期 -, 页码 -出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2023.101057
关键词
Indolent ATLL; CLL; Monoclonal B-cell lymphocytosis; Early therapeutic intervention
类别
Adult T-cell leukemia/lymphoma (ATLL) has aggressive clinical behaviors. A progression model from asymptomatic human T-cell leukemia virus type 1 carrier to aggressive ATLL has been proposed. Indolent ATLL has unsatisfactory long-term prognosis and warrants further treatment strategies, including precision medicine. Unlike indolent ATLL, several molecular-targeted agents have dramatically improved chronic lymphocytic leukemia (CLL) prognosis.
Adult T-cell leukemia/lymphoma (ATLL) has aggressive clinical behaviors, and improving its prognosis is a great challenge. A disease progression model from asymptomatic human T-cell leukemia virus type 1 carrier to aggressive-type ATLL has been proposed, and indolent ATLL comprising a smoldering or favorable chronic type is located at the midpoint. Even the most favorable smoldering type has a 4-year overall survival rate of <60%. Although watchful waiting is pervasive in patients with indolent ATLL, early therapeutic intervention is discussed among hematologists. Indolent ATLL was once termed T-cell-derived chronic lymphocytic leukemia (CLL). Unlike indolent ATLL, several molecular-targeted agents at the initial treatment have dramatically improved CLL prognosis. Recent studies on CLL have revealed a similar progression model involving premalignant monoclonal B-cell lymphocytosis (MBL). In particular, individuals with high-count MBL have an increased lymphoma risk. Considering the unsatisfactory long-term prognosis of indolent ATLL, further treatment strategies, including precision medicine, are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据